search
Back to results

Preventing Outcomes Through Effective Cardiovascular Risk Reduction After Transplant II (PROTECTII)

Primary Purpose

Hypertension

Status
Completed
Phase
Not Applicable
Locations
United States
Study Type
Interventional
Intervention
Ambulatory Blood Pressure Monitoring
Sponsored by
University of Michigan
About
Eligibility
Locations
Arms
Outcomes
Full info

About this trial

This is an interventional prevention trial for Hypertension focused on measuring hypertension, kidney disease, cardiovascular disease

Eligibility Criteria

18 Years - undefined (Adult, Older Adult)All SexesDoes not accept healthy volunteers

Inclusion Criteria:

  • All adult (age > 18 years) live donor candidates being evaluated by the U of M transplant center
  • All adult (age > 18 years)kidney/kidney-pancreas candidates being evaluated by the U of M transplant center
  • All adult (age >18 years) live donors or successful kidney/kidney-pancreas recipients.

Exclusion Criteria:

  • Inability to provide informed consent

Sites / Locations

  • UMichigan

Arms of the Study

Arm 1

Arm Type

Experimental

Arm Label

Ambulatory Blood Pressure Monitoring

Arm Description

All enrolled patients have an ambulatory blood pressure monitor placed, pre-transplant/donation, again at 3 months and finally at 12 months post-transplant/donation to measure blood pressure and blood pressure patterns

Outcomes

Primary Outcome Measures

Change in ABPM pattern following donation/transplantation
We reassessed the ABPM pattern prior to, early after and 12 months after kidney transplant or live kidney donation to look for changes consistent with onset hypertension

Secondary Outcome Measures

Fatal and Non-Fatal Cardiovascular Events
Fatal and non-fatal cardiovascular events, including myocardial infarction, congestive heart failure, coronary angioplasty, coronary artery bypass grafting, cardiac arrhythmias, sudden cardiac death, transient ischemic attack, stroke, carotid endarterectomy, aortic dissection, new peripheral vascular disease diagnosis or intervention.
Death
Death from any cause
Allograft Failure
Allograft failure, regardless of cause
kidney function
kidney function calculated at 12 months post-donation or post-transplant

Full Information

First Posted
December 2, 2013
Last Updated
February 21, 2017
Sponsor
University of Michigan
search

1. Study Identification

Unique Protocol Identification Number
NCT02003469
Brief Title
Preventing Outcomes Through Effective Cardiovascular Risk Reduction After Transplant II
Acronym
PROTECTII
Official Title
Preventing Outcomes Through Effective Cardiovascular Risk Reduction After Transplant II
Study Type
Interventional

2. Study Status

Record Verification Date
February 2017
Overall Recruitment Status
Completed
Study Start Date
April 2009 (undefined)
Primary Completion Date
September 2013 (Actual)
Study Completion Date
September 2013 (Actual)

3. Sponsor/Collaborators

Responsible Party, by Official Title
Principal Investigator
Name of the Sponsor
University of Michigan

4. Oversight

Studies a U.S. FDA-regulated Drug Product
No
Studies a U.S. FDA-regulated Device Product
No
Data Monitoring Committee
Yes

5. Study Description

Brief Summary
Background and Rationale Cardiovascular disease is highly prevalent in the kidney transplant population, accounting for approximately 40% of all deaths and significant morbidity. The morbidity and mortality experienced by kidney transplant recipient's results from an excess of pre-transplant risk factors that are exacerbated by kidney transplantation along with the development of novel risk factors. Hypertension (HTN) is the most consistent cardiovascuar disease risk factor in transplant recipients.. A large number of studies have been done in the general population comparing ambulatory blood pressure monitoring (ABPM) to casual, office based and home measures of blood pressure (BP). The results have clearly demonstrated that ABPM gives a more accurate representation of BP and arguably should be used as part of routine patient care. ABPM has been shown to reveal patients both with white-coat and with masked HTN, nocturnal HTN and lack of nocturnal dipping. Ambulatory BP measures afford us a non-invasive, highly accurate way to evaluate and treat kidney transplant recipients. Live kidney donors (LKD) have significantly expanded the supply of critical organs. Of paramount importance of course has always been donor safety. As a result, candidates are known to be healthy at the time of donation. Ambulatory blood pressure monitoring allows a unique opportunity to examine the effects of live kidney donation on the blood pressure profiles of LKD. Methods Study Design: Prospective, 5-year, single center study of ABPM, cardiovascular and graft outcomes in incident and prevalent live kidney donors, kidney and kidney-pancreas transplant candidates and recipients.
Detailed Description
Background and Rationale Cardiovascular disease is highly prevalent in the kidney transplant population, accounting for approximately 40% of all deaths and significant morbidity. The morbidity and mortality experienced by kidney transplant recipients results from an excess of pre-transplant risk factors that are exacerbated by kidney transplantation along with the development of novel risk factors. Hypertension (HTN) is the most consistent cardiovascular disease risk factor in transplant recipients. The majority of patients with kidney failure have HTN and close to 30,000 individuals annually have HTN as the primary cause of kidney failure. A number of immunosuppressive medications exacerbate HTN after transplantation. Further, there is a clear effect of declining allograft function on cardiovascular disease risk. A large number of studies have been done in the general population comparing ambulatory blood pressure monitoring (ABPM) to casual, office based and home measures of blood pressure (BP). The results have clearly demonstrated that ABPM gives a more accurate representation of BP and arguably should be used as part of routine patient care. ABPM has been shown to reveal patients both with white-coat and with masked HTN, nocturnal HTN and lack of nocturnal dipping. The information has been successfully used to more accurately and aggressively treat patients. Compared to the general population, the data in the kidney transplant population is relatively limited. Ambulatory BP measures afford us a non-invasive, highly accurate way to evaluate and treat kidney transplant recipients. Live kidney donors (LKD) have significantly expanded the supply of critical organs. Of paramount importance of course has always been donor safety. A significant amount of time goes into the screening and evaluation of live donor candidates. As a result, candidates are known to be healthy at the time of donation. Following donation, however, there is less known about outcome. Historically, there has been no nationalized, systematic mechanism for following LKD. What is known to date is the result of largely single-center, retrospective studies. There is a documented incidence of kidney failure and proteinuria and increased prevalence of HTN. There are no longitudinal studies of the effect of kidney donation on blood pressure. Ambulatory blood pressure monitoring allows a unique opportunity to examine the effects of live kidney donation on the blood pressure profiles of LKD. Significance Cardiovascular disease is the major cause of death in kidney transplant recipients. Methods to better define, describe and modify cardiovascular risk factors in this population are essential. Ambulatory blood pressure monitoring allows us the best method to better define our at-risk population, to better understand the relationship of HTN in kidney transplant recipients and end-organ consequences and to define appropriate surrogate markers. There is also a role for using specific medication classes that have been shown to reestablish a more normal circadian BP pattern in monitored patients. Utilization of ABPM, in this population has the potential to advance medical research and to decrease morbidity and mortality in kidney transplant recipients. Live kidney donors have an unknown cardiovascular risk. Retrospective studies that document a low overall risk of death may not capture the morbidity that may be associated with kidney donation. In addition, the low mortality in LKD may still exceed what would be expected on the basis of the initial low risk of donor candidates. One of the most easily measurable and modifiable factors that can contribute to cardiovascular risk is blood pressure. Accurate measurement of LKD blood pressure pattern would allow better understanding of the effect of live donation on HTN risk and provide the necessary information to modify and improve the outcomes of LKD. Methods Study Design: Prospective, 5-year, single center study of ABPM, cardiovascular and graft outcomes in incident and prevalent live kidney donors, kidney and kidney-pancreas transplant candidates and recipients. Anticipated enrollment: 1,000 subjects Inclusion Criteria: All live donor candidates and kidney/kidney-pancreas candidates being evaluated by the U of M transplant center and successful kidney/kidney-pancreas recipients. Intervention (Recipients): As part of standard University of Michigan Transplant Center protocol, all kidney/kidney-pancreas transplant recipients have 24-hour ABPM done approximately 3 and 12 months post-transplant and annually thereafter. Pre-transplant recipient candidates enrolled will consent to an additional ABPM measure to be done prior to transplantation. Enrolled recipient subjects will allow access to their ABPM and medical records for research and will consent to study blood draws with each ABPM placement and at the time of any kidney biopsy. In addition, recipients will have urine collected to examine for markers of renal dysfunction prior to and following transplantation. Intervention (Donors): Donor candidates will consent to having 3 ABPM measurements done. Donor candidates will have the first ABPM placed prior to donation, with additional ABPM measures done at 3 and 12 months post-donation. Enrolled donor subjects will also consent to release of donor medical records for research. Donors will consent to study blood draws at the time of each ABPM placement along with urine collection prior to and following donation. Samples may be stored in the U of M, Division of Nephrology Bio-bank for future research efforts.

6. Conditions and Keywords

Primary Disease or Condition Being Studied in the Trial, or the Focus of the Study
Hypertension
Keywords
hypertension, kidney disease, cardiovascular disease

7. Study Design

Primary Purpose
Prevention
Study Phase
Not Applicable
Interventional Study Model
Single Group Assignment
Masking
None (Open Label)
Allocation
N/A
Enrollment
67 (Actual)

8. Arms, Groups, and Interventions

Arm Title
Ambulatory Blood Pressure Monitoring
Arm Type
Experimental
Arm Description
All enrolled patients have an ambulatory blood pressure monitor placed, pre-transplant/donation, again at 3 months and finally at 12 months post-transplant/donation to measure blood pressure and blood pressure patterns
Intervention Type
Device
Intervention Name(s)
Ambulatory Blood Pressure Monitoring
Other Intervention Name(s)
Spacelabs Healthcare ambulatory blood pressure monitors
Intervention Description
All enrolled patients have an ambulatory blood pressure monitor placed, pre-transplant/donation, again at 3 months and finally at 12 months post-transplant/donation to measure blood pressure and blood pressure patterns
Primary Outcome Measure Information:
Title
Change in ABPM pattern following donation/transplantation
Description
We reassessed the ABPM pattern prior to, early after and 12 months after kidney transplant or live kidney donation to look for changes consistent with onset hypertension
Time Frame
12 months
Secondary Outcome Measure Information:
Title
Fatal and Non-Fatal Cardiovascular Events
Description
Fatal and non-fatal cardiovascular events, including myocardial infarction, congestive heart failure, coronary angioplasty, coronary artery bypass grafting, cardiac arrhythmias, sudden cardiac death, transient ischemic attack, stroke, carotid endarterectomy, aortic dissection, new peripheral vascular disease diagnosis or intervention.
Time Frame
5 years
Title
Death
Description
Death from any cause
Time Frame
5 years
Title
Allograft Failure
Description
Allograft failure, regardless of cause
Time Frame
5 years
Title
kidney function
Description
kidney function calculated at 12 months post-donation or post-transplant
Time Frame
12 months

10. Eligibility

Sex
All
Minimum Age & Unit of Time
18 Years
Accepts Healthy Volunteers
No
Eligibility Criteria
Inclusion Criteria: All adult (age > 18 years) live donor candidates being evaluated by the U of M transplant center All adult (age > 18 years)kidney/kidney-pancreas candidates being evaluated by the U of M transplant center All adult (age >18 years) live donors or successful kidney/kidney-pancreas recipients. Exclusion Criteria: Inability to provide informed consent
Overall Study Officials:
First Name & Middle Initial & Last Name & Degree
Silas P Norman, MD, MPH
Organizational Affiliation
University of Michigan
Official's Role
Principal Investigator
Facility Information:
Facility Name
UMichigan
City
Ann Arbor
State/Province
Michigan
ZIP/Postal Code
48109
Country
United States

12. IPD Sharing Statement

Plan to Share IPD
No
Citations:
PubMed Identifier
16815854
Citation
Marcen R. Cardiovascular risk factors in renal transplantation--current controversies. Nephrol Dial Transplant. 2006 Jul;21 Suppl 3:iii3-8. doi: 10.1093/ndt/gfl298.
Results Reference
background
PubMed Identifier
16129216
Citation
Jardine AG, Fellstrom B, Logan JO, Cole E, Nyberg G, Gronhagen-Riska C, Madsen S, Neumayer HH, Maes B, Ambuhl P, Olsson AG, Pedersen T, Holdaas H. Cardiovascular risk and renal transplantation: post hoc analyses of the Assessment of Lescol in Renal Transplantation (ALERT) Study. Am J Kidney Dis. 2005 Sep;46(3):529-36. doi: 10.1053/j.ajkd.2005.05.014.
Results Reference
background

Learn more about this trial

Preventing Outcomes Through Effective Cardiovascular Risk Reduction After Transplant II

We'll reach out to this number within 24 hrs